The EVs from CLL cells show a mRNA enrichment for kinases of the BCR pathway and the EV release might be influenced by kinases of the BCR pathway, since treatment with inhibitors of BTK and PI3K reduces the plasma EV count in CLL patients. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.